Here you get to Know about the Profile of Sun Pharmaceutical Industries Limited and their Products and Brands.
Sun Pharma Company
Sun Pharmaceutical Industries Limited is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
Sun Pharma continues to be the undisputed industry leader in India, enjoying an 8.2% share of the market. The Company is also the market leader in the chronic segment.
Sun Pharma Products
The Company is deepening its global footprint as a highly trusted manufacturer of following Products
- Specialty products,
- Branded generics,
- Complex and pure generics,
- OTC products,
- Antiretrovirals (ARVs) and
It is expanding its footprint among consumers and healthcare professionals in 100+ countries, and offers a portfolio of 2,000+ products, globally, in a full range of dosage forms.
Sun Pharma Top Products
- Creams and
- Nasal sprays and
- Hormones, among others.
Sun Pharma has 44 manufacturing sites approved by global health regulatory agencies—supported by a worldwide supply chain—and multiple research and development (R&D) facilities across the world, investing 6.9% of its sales in R&D. I
t has a diverse employee base of 32,000+ individuals across 50 nationalities worldwide. It has manufacturing units located in India, the US, Canada, Japan, Hungary, Israel, Russia, Egypt, Bangladesh, Nigeria, South Africa, Malaysia, and Australia.
Sun Pharm is the fourth-largest company in the world based generic sales.
Sun Pharma Owner: Dilip Shanghvi
Dilip Shanghvi is currently the managing director of Sun Pharmaceuticals. Dilip Shanghvi, in full Dilip Shantilal Shanghvi, (born October 1, 1955, Amreli, Gujarat state, India), Indian business executive who was the founder (1983) of Sun Pharmaceutical Industries Ltd.
The son of a wholesale drug distributor, Shanghvi launched Sun Pharma soon after graduating (1982) from the University of Calcutta with a bachelor’s degree in commerce. He assumed the post of managing director. Initially, the company marketed only a small number of psychiatric drugs, but by the early 1990s, it had opened its own research and manufacturing facilities and added product lines in the fields of cardiology and gastroenterology.
Shanghvi took the company public in 1994. Three years later Sun Pharma made its first international acquisition when it bought Detroit-based Caraco Pharmaceutical Laboratories; it also took equity stakes in two prominent Indian drug manufacturers, Tamilnadu Dadha Pharmaceuticals and MJ Pharmaceuticals.
Portfolio of 300+ approved DMF/CEP products. Active Pharmaceutical Ingredients (API) contribute about 6 % of the revenue of the company. The company has 14 API manufacturing Facilities and one of the leading manufacturers of API.
Subsidiaries of Sun Pharma
Below is the list of major subsidiaries of Sun pharmaceuticals.